# Boundless Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/boundless-bio

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.boundlessbio.com/
- Total disclosed funding: $228M
- Latest round: Series C (May 16, 2023)
- Investors on record: 17

## About

Boundless Bio, Inc., based in the US, focuses on advancing precision oncology through innovative therapies targeting oncogene amplified cancers, leveraging its proprietary Spyglass platform.Founded in 2019 and headquartered in San Diego, US, Boundless Bio, Inc. is dedicated to developing next-generation oncology therapies. The company successfully raised USD 100 mn in its latest funding round, the Series C, on March 27, 2024, and has completed a total of 5 deals to date. The company was founded by Keith Lenden, with Zachary Hornby serving as CEO.Boundless Bio specializes in developing next-generation precision oncology therapies, particularly ecDNA-directed therapies (ecDTx) that target oncogene amplified cancers characterized by extrachromosomal DNA (ecDNA). Using the proprietary Spyglass platform, Boundless Bio identifies vulnerabilities in cancer cells reliant on ecDNA, enabling the design of therapies specifically targeting these weaknesses. Their product offerings aim to enhance treatment outcomes for patients facing these aggressive cancer types, catering to healthcare providers and research institutions globally, including regions in North America, Europe, and Asia.In the most recent year, 2023, Boundless Bio reported revenue of USD 0, with an EBITDA of USD -57.14 mn. The company engages in partnerships with healthcare providers and research institutions, likely employing revenue-sharing models from successful clinical trials or product sales, though specific financial details of these collaborations have not been disclosed.Following a successful IPO on March 27, 2024, where Boundless Bio, Inc. raised USD 100 mn by selling 6.25 million shares at USD 16 each, the company aims to utilize this funding to accelerate the development of its ecDNA therapies and expand its market presence. The IPO allowed key investors such as ARCH Venture Partners and Fidelity Investments to retain significant minority stakes, reinforcing their commitment to the company's future. As Boundless Bio continues to innovate in the oncology sector, they plan to target new geographic markets, enhancing access to their therapeutic offerings in regions where oncogene amplified cancers are prevalent.

## Funding rounds

- Series C, May 16, 2023, $100M — ARCH Venture Partners, Alexandria Venture Investments, Wellington Management, Nextech, Fidelity Investments, Surveyor Capital, Redmile Group, City Hill Ventures, Sectoral Asset Management, RA Capital Management, Vertex Ventures, GT Healthcare Capital Partners, Leaps by Bayer, Logos Capital, PFM Health Sciences, Piper Heartland Healthcare Capital
- Series B, Apr 28, 2021, $105M — ARCH Venture Partners, Alexandria Venture Investments, Wellington Management, Nextech, Fidelity Investments, Surveyor Capital, Redmile Group, City Hill Ventures, RA Capital Management, Vertex Ventures, Boxer Capital, GT Healthcare Capital Partners, Logos Capital, PFM Health Sciences
- Series A, Sep 19, 2019, $23M — ARCH Venture Partners, Alexandria Venture Investments, City Hill Ventures, Vertex Ventures, Boxer Capital, GT Healthcare Capital Partners

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A, Series B, Series C
- City Hill Ventures (https://capitalatlas.ai/funds/city-hill-ventures) — Series A, Series B, Series C
- Vertex Ventures (https://capitalatlas.ai/funds/vertex-ventures) — Series A, Series B, Series C
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series A, Series B
- GT Healthcare Capital Partners (https://capitalatlas.ai/funds/gt-healthcare-capital-partners) — Series A, Series B, Series C
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series B, Series C
- Nextech (https://capitalatlas.ai/funds/nextech) — Series B, Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B, Series C
- Surveyor Capital — Series B, Series C
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B, Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B, Series C
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B, Series C
- PFM Health Sciences (https://capitalatlas.ai/funds/pfm-health-sciences) — Series B, Series C
- Sectoral Asset Management (https://capitalatlas.ai/funds/sectoral-asset-management) — Series C
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series C
- Piper Heartland Healthcare Capital — Series C